These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25441760)

  • 1. [PARP inhibitors and radiotherapy: rational and prospects for a clinical use].
    Pernin V; Mégnin-Chanet F; Pennaneach V; Fourquet A; Kirova Y; Hall J
    Cancer Radiother; 2014 Dec; 18(8):790-8; quiz 799-802. PubMed ID: 25441760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [PARP inhibitors for cancer therapy].
    Saito H; Miki Y
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):12-8. PubMed ID: 21368455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [PARP inhibitors: significant progress in cancer therapy].
    Dantzer F; Noel G; Schreiber V
    Bull Cancer; 2011 Mar; 98(3):277-90. PubMed ID: 21459712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP inhibitors in breast cancer: BRCA and beyond.
    Rios J; Puhalla S
    Oncology (Williston Park); 2011 Oct; 25(11):1014-25. PubMed ID: 22106552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting poly(ADP-ribose) polymerase activity for cancer therapy.
    Mégnin-Chanet F; Bollet MA; Hall J
    Cell Mol Life Sci; 2010 Nov; 67(21):3649-62. PubMed ID: 20725763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
    Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
    Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential of PARP inhibitors in genetic breast and ovarian cancers.
    Drew Y; Calvert H
    Ann N Y Acad Sci; 2008 Sep; 1138():136-45. PubMed ID: 18837894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA in breast cancer: from risk assessment to therapeutic prediction.
    Diamond JR; Borges VF; Eckhardt SG; Jimeno A
    Drug News Perspect; 2009 Dec; 22(10):603-8. PubMed ID: 20140280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly(ADP-ribose)polymerase (PARP) inhibitors: from bench to bedside.
    Plummer R
    Clin Oncol (R Coll Radiol); 2014 May; 26(5):250-6. PubMed ID: 24602564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation.
    Mangerich A; Bürkle A
    Int J Cancer; 2011 Jan; 128(2):251-65. PubMed ID: 20853319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
    Yap TA; Sandhu SK; Carden CP; de Bono JS
    CA Cancer J Clin; 2011; 61(1):31-49. PubMed ID: 21205831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.
    Chionh F; Mitchell G; Lindeman GJ; Friedlander M; Scott CL
    Asia Pac J Clin Oncol; 2011 Sep; 7(3):197-211. PubMed ID: 21884432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [On the prospects of using the DNA repair inhibitors in radiotherapy of tumors].
    Gaziev AI
    Radiats Biol Radioecol; 2014; 54(3):229-40. PubMed ID: 25764827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP Inhibitors: The Cornerstone of DNA Repair-Targeted Therapies.
    del Rivero J; Kohn EC
    Oncology (Williston Park); 2017 Apr; 31(4):265-73. PubMed ID: 28412778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers.
    Powell C; Mikropoulos C; Kaye SB; Nutting CM; Bhide SA; Newbold K; Harrington KJ
    Cancer Treat Rev; 2010 Nov; 36(7):566-75. PubMed ID: 20409643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A snapshot of chemoresistance to PARP inhibitors.
    Chiarugi A
    Trends Pharmacol Sci; 2012 Jan; 33(1):42-8. PubMed ID: 22055391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP inhibitors in ovarian cancer: current status and future promise.
    Liu JF; Konstantinopoulos PA; Matulonis UA
    Gynecol Oncol; 2014 May; 133(2):362-9. PubMed ID: 24607283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [PARP inhibitors and breast cancer: update and perspectives].
    Gonçalves A
    Bull Cancer; 2012 Apr; 99(4):441-51. PubMed ID: 22450359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly (ADP-ribose) polymerase (PARP): rationale, preclinical and clinical evidences of its inhibition as breast cancer treatment.
    Orlando L; Schiavone P; Fedele P; Calvani N; Nacci A; Cinefra M; D'Amico M; Mazzoni E; Marino A; Sponziello F; Morelli F; Lombardi L; Silvestris N; Cinieri S
    Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S83-9. PubMed ID: 22443171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.